Featured Content

  • Unlock: TED@BCG Mumbai—2019

    Our speakers explore what it means to unlock human potential through the lenses of science, technology, social impact, media, and business.

  • What’s Trending in Jobs and Skills

    What we learned from analyzing 95 million online job postings over the past three years.

  • Winning the ’20s

    The winners in business have shifted markedly in the past decade—and the keys to success are likely to be very different again in ten years’ time. How should leaders prepare their companies to thrive in a rapidly evolving landscape? What will it take to win the '20s?

Wybierz swoją lokalizację, abyśmy mogli dostosować dla Ciebie wyniki wyszukiwania.

Zapamiętaj moją lokalizację oraz ustawienia językowe.

Najnowsze poglądy na temat biofarmaceutyków

Branże biotechnologii oraz farmaceutyki kontynuują swoją szybką ewolucję cyfrową. Siły geopolityczne oraz ekonomiczne stanowią jednak dla nich przeszkody, które wymagają precyzyjnej strategii w całym łańcuchu dostaw. Poznaj świadome przywództwo BCG w dziedzinie biofarmaceutyków, by uzyskać informacje na temat przyszłości branży biotechnologicznej.

DIGITAL & ANALYTICS

COMMERCIAL

OPERATIONS

RESEARCH & DEVELOPMENT


Featured Insights

Agile Can Work Wonders in Pharma
Read the article

Early-Stage Investments Could Use the AI Touch

Read the article

Disrupting from Within: Allergan’s Digital Journey

Watch the interview

Women Dominate Health Care—Just Not in the Executive Suite

Read the article

Digital & Analytics

Chasing Value as AI Transforms Health Care

Chasing Value as AI Transforms Health Care

The revolution has come to health care. Artificial intelligence has major repercussions for players across the industry—as well as for new-technology entrants and consumers.

Commercial

Operations

How US Tax Reform Will Affect Biopharma Supply Chains

How US Tax Reform Will Affect Biopharma Supply Chains

Supply chain managers need to ask certain key questions about how the new law will affect their companies’ global networks, investments, and M&A strategies—giving them a better understanding of how to make winning moves.

Research & Development

Placing Your CAR-T Bets

Placing Your CAR-T Bets

These new therapies are poised to revolutionize oncology. It all depends on reaching a larger patient base and simplifying manufacturing and the supply chain.

What is the Right Amount to Spend on Biopharma R&D?

What Is the Right Amount to Spend on Biopharma R&D?

The most successful companies are those with flexible R&D allocation, according to BCG’s Michael Ringel in an article published in Nature Reviews Drug Discovery. These companies actively pursue and invest in the right new scientific opportunities, balance quantitative and qualitative information on scientific feasibility and market need, employ incentives that drive “truth seeking,” and introduce variability into the cost base to enable flexibility in year-to-year investment levels.

BCG GAMMA's Transformative Work for an Oncology Center

BCG GAMMA's Transformative Work for an Oncology Center

Using Big Data to Help Fight Cancer

Innovation in Biopharma R&D

Zewnętrzne podstawy innowacji oczami specjalisty ds. badań i rozwoju

Karalee Close on The Digital Opportunity in Healthcare

Frank Cordes on The Pharma Factory of the Future

Mark Lubkeman on A Return to Growth

BCG GAMMA developed an advanced analytics solution and innovative digital tool by using AI techniques, machine learning algorithms, and marketing strategies to help an oncology center.
Next Section: Solutions
Addressing a Changing Market
Open BCG’s toolkit of real-world solutions for biopharma companies.
protected by reCaptcha

Subscribe to our Biopharma eAlert.

Subscribed

Click to Manage Your Subscriptions.
Produkty biofarmaceutyczne

SUBSCRIBE

PL

Ta strona korzysta z plików "cookies" w celu poprawienia funkcjonalności i działania. Decydując się na dalsze korzystanie z tej strony, jednocześnie zgadzasz się z użyciem plików "cookies" przez tą stronę. Zobacz naszą Politykę Cookies, żeby dowiedzieć się więcej.